Grifols divests its hemostasis technology business for USD 25 million

- The transaction is part of Grifols' previously announced plan to divest in non-strategic activities
- Grifols hemostasis and coagulation product line, integrated in the Diagnostic Division, had been marketed by an external distributor since 2018

**Barcelona, October 6, 2021.**- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a leading global healthcare company with a more than 110-year track record contributing to the health and well-being of people, and an industry forerunner in plasma-derived medicines, transfusion diagnostics and hospital pharmacy solutions, has agreed to sell its hemostasis business for approximately USD 25 million in cash as part of its previously announced divestment process of non-strategic assets.

The transaction comprises all assets related to the diagnosis of hemostasis disorders, including the tests (reagents) and their associated intellectual property, R&D projects and manufacturing know-how, and the instruments (analyzers) used to automate diagnostic coagulation tests. The divestment also includes all Grifols' hemostasis-related R&D and manufacturing equipment. A workforce of 25 employees has been transferred to the new entity as well.

This product portfolio, known for its high reliability and efficiency, had been marketed by an external distributor since 2018.

The transaction is effective October 1, 2021.

Grifols will continue to evaluate its product portfolio and prioritize growth and profitability in alignment with its long-term value creation strategy.

The company retained Osborne Clarke, S.L.P. as legal advisors for this transaction.

---

**Investor contact:**

Investor Relations and Sustainability

[investors@grifols.com](mailto:investors@grifols.com) - [sustainability@grifols.com](mailto:sustainability@grifols.com)

Tel. +34 93 571 02 21
About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with close to 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2020, Grifols’ economic impact in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced jobs.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit [www.grifols.com](http://www.grifols.com)

---

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing.
this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.